Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu


Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown Portsmouth, New Hampshire

Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2022 results on Tuesday, May 3, 2022, after the close of the market. Acadia will conduct a

Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2022 financial results on Wednesday, May 4th, before the market opens. A conference call has been scheduled to

DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures': http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the

LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures


LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the start of a targeted commercial launch for the

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields


Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held

DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb
Chemed To Report First-Quarter 2022 Earnings April 26, Related Conference Call To Be Held On April 27:
Chemed To Report First-Quarter 2022 Earnings April 26, Related Conference Call To Be Held On April 27


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2022, on Tuesday, April 26, 2022, following the close of trading on the

Charles River Laboratories Publishes 2021 Corporate Citizenship Report: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Publishes 2021 Corporate Citizenship Report


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2021 Corporate Citizenship Report. The 2021 report demonstrates Charles River’s priorities and

DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022: https://mms.businesswire.com/media/20201201005032/en/841855/5/AMN-Logo.jpg
AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022


AMN Healthcare Services, Inc. (NYSE: AMN) has scheduled a conference call to discuss its first quarter 2022 financial results and second quarter 2022 outlook on Thursday, May 5, 2022 at 5:00 p.m

Charles River Laboratories Acquires Explora BioLabs: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Acquires Explora BioLabs


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Explora BioLabs Holdings, Inc., a premier provider of contract vivarium research services.



Based in

DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 third quarter on Tuesday, May 3, 2022, at approximately 6:30 a.m. ET. The company will also

DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022
DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022
DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022
DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve

Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that its Board of Directors has named Christopher Hunter as the Company’s new Chief Executive Officer. He will join Acadia on April

Novocure to Report First Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report First Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease: https://mms.businesswire.com/media/20200601005592/en/794449/5/RRD_LOGO_tagline_TM-CMYK_Black_highres.jpg
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease


Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce

Recordati Rare Diseases: Ergebnisse der Phase-III-Studie LINC 4 im Journal of Clinical Endocrinology & Metabolism veröffentlicht; Bestätigung der Wirksamkeit und Sicherheit von Isturisa® (Osilodrostat) bei Patienten mit Morbus Cushing: https://mms.businesswire.com/media/20200601005592/en/794449/5/RRD_LOGO_tagline_TM-CMYK_Black_highres.jpg
Recordati Rare Diseases: Ergebnisse der Phase-III-Studie LINC 4 im Journal of Clinical Endocrinology & Metabolism veröffentlicht; Bestätigung der Wirksamkeit und Sicherheit von Isturisa® (Osilodrostat) bei Patienten mit Morbus Cushing


Recordati Rare Diseases gibt heute die Veröffentlichung der positiven Ergebnisse der Phase-III-Studie LINC 4 zu Isturisa im The Journal of Clinical Endocrinology & Metabolism.1 bekannt. Diese Daten